Aurinia Pharmaceuticals Inc. — Company profile
Healthcare · Biotechnology · Canada
Last price 16.3 USD (Nov 2, 2026, 10:34 AM EST) · Market cap 2.18B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Details
| Name | Aurinia Pharmaceuticals Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 128 |
| Founded | 1993 |
| Ipo Date | 1999-01-26 |
| Ceo | Kevin Tang |
| Country | Canada |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | CA05156V1022 |
| Cusip | 05156V102 |
| Cik | 0001600620 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Kevin C. Tang | Chairman and Chief Executive Officer |
| Stephen P. Robertson | Chief Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Peter S. Greenleaf M.B.A. | Consultant |
| Ryan Cole | Chief Operating Officer |
| Thomas Wei | Chief Scientific Officer |
| Stewart M. Kroll | Chief Development Officer |
Contact
| Address | #140, 14315 – 118 Avenue, Edmonton, AB T5L 4S6, Canada |
| Phone | 250 744 2487 |
| Website | https://www.auriniapharma.com |